Drug intelligence / Profile preview

ABI-010

Development stage: Discontinued
Lead developer: Bristol Myers Squibb
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Intravenous

Overview

ABI-010 is a nanoparticle albumin-bound formulation of 17-AAG (tanespimycin), which acts as an inhibitor of the heat shock protein 90 (HSP90). HSP90 is a molecular chaperone involved in the stabilization and function of several proteins required for tumor growth. By inhibiting HSP90, ABI-010 disrupts multiple signaling pathways critical for cancer cell survival and proliferation. The drug was developed primarily for the treatment of advanced malignant solid neoplasms but its clinical development was discontinued after Phase 1 trials[1].

Other names: Nab-17-AAGNab17-AAGNab 17-AAG

Targets

HSP90 (Heat shock protein 90 chaperone complex)

Beyond the preview

Go deeper on ABI-010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABI-010.

Explore the full profile